Azacitidine Post-Remission Therapy for Elderly Patients with AML: A Randomized Phase-3 Trial (QoLESS AZA-AMLE)

SIMPLE SUMMARY: Azacitidine (AZA) is a hypomethylating agent with well-known antileukemic activity. Due to its favorable safety profile, AZA is widely used alone or in association with other drugs for the frontline treatment of patients with acute myeloid leukemia (AML) unfit for intensive chemother...

Descripción completa

Detalles Bibliográficos
Autores principales: Oliva, Esther Natalie, Candoni, Anna, Salutari, Prassede, Palumbo, Giuseppe A., Reda, Gianluigi, Iannì, Giuseppe, Tripepi, Giovanni, Cuzzola, Maria, Capelli, Debora, Mammì, Corrado, Alati, Caterina, Cannatà, Maria Concetta, Niscola, Pasquale, Serio, Bianca, Musto, Pellegrino, Vigna, Ernesto, Volpe, Antonio, Melillo, Lorella Maria Antonia, Arcadi, Maria Teresa, Mannina, Donato, Zannier, Maria Elena, Latagliata, Roberto
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10177242/
https://www.ncbi.nlm.nih.gov/pubmed/37173908
http://dx.doi.org/10.3390/cancers15092441

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10177242/
https://www.ncbi.nlm.nih.gov/pubmed/37173908
http://dx.doi.org/10.3390/cancers15092441

Ejemplares similares